AlloTribe

AlloTribe is an early-stage biotechnology company pioneering the use of allosteric regulation in synthetic biology to develop next-generation cell therapies. By engineering cells with sophisticated molecular switches, the company aims to create "programmable" medicines that can be precisely controlled within the body to improve safety and efficacy. Founded by leading researchers from UCSF and Boston University, AlloTribe is focused on addressing the challenges of current CAR-T and other cell-based treatments in oncology and beyond. The company is backed by top-tier life science investors, including ARCH Venture Partners and F-Prime Capital, and is currently advancing its platform through the pre-clinical stage. Their approach involves designing synthetic receptors that can be toggled between active and inactive states, providing a mechanism to mitigate toxicities like cytokine release syndrome.